Beam Therapeutics Outlines 2026 Strategy, Shares Surge 23.67%

Written by Emily J. Thompson, Senior Investment Analyst

BEAM+2.55%

BMY+0.27%

Source: Benzinga

Updated: 1d ago

0mins

Source: Benzinga

FDA Progress: Beam Therapeutics has aligned with the FDA on a potential accelerated approval pathway for BEAM-302, planning to file a Biologics License Application by the end of 2026, which could significantly advance treatment for alpha-1 antitrypsin deficiency.
Clinical Trial Expansion: The company intends to enroll approximately 50 additional patients in an expanded Phase 1/2 study to optimize the biologic dose, thereby enhancing its competitive position in the market.
Strong Financial Position: Beam estimates it will end 2025 with around $1.25 billion in cash and equivalents, sufficient to support operations and capital needs into 2029, ensuring funding for the upcoming drug launch.
Robust Stock Performance: Beam Therapeutics shares rose 23.67% to $34.07, nearing its 52-week high of $35.25, indicating strong short-term momentum and solid long-term growth potential.

BEAM

$34.55+Infinity%1D

Analyst Views on BEAM

Wall Street analysts forecast BEAM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BEAM is 41.90 USD with a low forecast of 21.00 USD and a high forecast of 80.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

13 Analyst Rating

11 Buy

2 Hold

0 Sell

Strong Buy

Current: 33.690

Low

21.00

Averages

41.90

High

80.00

Current: 33.690

Low

21.00

Averages

41.90

High

80.00

UBS

Michael Yee

Neutral

initiated

$28

2026-01-07

Reason

UBS

Michael Yee

Price Target

$28

2026-01-07

initiated

Neutral

Reason

UBS analyst Michael Yee initiated coverage of Beam Therapeutics (BEAM) with a Neutral rating and $28 price target as the analyst initiated or assumed coverage on 22 small-to-mid cap biotech names. After a rough period, biotech fundamentals are now inflecting, contends the analyst, who expects investor confidence to recover and sees this positioning biotech for strong performance in 2026. Among the group, top picks include Apogee Therapeutics (APGE), Cogent Biosciences (COGT), Kodiak Sciences (KOD), Ideaya Biosciences (IDYA), Inventiva (IVA), SAB Biotherapeutics (SABS) and Ventyx Biosciences (VTYX), which the analyst highlights as having key upcoming catalysts, de-risked best-in-class portfolios, strong data, and broader pipelines.

BofA

Alec Stranahan

Buy

maintain

$43 -> $45

2026-01-06

Reason

BofA

Alec Stranahan

Price Target

$43 -> $45

2026-01-06

maintain

Buy

Reason

BofA analyst Alec Stranahan raised the firm's price target on Beam Therapeutics to $45 from $43 and keeps a Buy rating on the shares. The firm is updating its price targets for U.S Biopharmaceuticals under its coverage, the analyst tells investors. Over the past few months, several key items "have fallen into place," including positive data catalysts being rewarded; large-cap biopharma spending cash on M&A and in-licensing; growing backlog of companies on the private side; improving access to capital; and limited impact from drug price regulation, BofA says. The firm believes biotech is back, but the biggest concern is whether this will last.

Evercore ISI

Outperform

initiated

$35

2025-11-24

Reason

Evercore ISI

Price Target

$35

2025-11-24

initiated

Outperform

Reason

Evercore ISI initiated coverage of Beam Therapeutics with an Outperform rating and $35 price target. BEAM-302 offers "a potentially game-changing approach for AATD," with early data showing impressive levels of corrected AAT production, says the analyst, who calls upcoming data due in Q1 of 2026 "crucial."

Clear Street

Buy

maintain

$34 -> $37

2025-11-04

Reason

Clear Street

Price Target

$34 -> $37

2025-11-04

maintain

Buy

Reason

Clear Street raised the firm's price target on Beam Therapeutics to $37 from $34 and keeps a Buy rating on the shares following the Q3 report. BEAM-103 has dosed the first patient in a healthy volunteer study while the next major catalyst for the shares being the interim update from BEAM-302 in early 2026, the analyst tells investors in a research note. Clear adds that Beam owns 17% of private company Orbital Therapeutics, which amounts to $255M in its recently announced takeout.

About BEAM

Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.